An open label trail of omega-3 fatty acid supplements for ADHD
In this study 9 children with were supplemented with 16.2 g EPA/DHA daily; the dosage was adjusted at 4 weeks based on the observed blood plasma ratio of arachidonic acid (AA) to EPA, the aim was for this ratio to reach a level normally found in the Japanese population. A psychiatrist reported significant improvements in behaviour (inattention, hyperactivity, oppositional/defiant behaviour, and conduct disorder); there was also a significant correlation between the reduction in the AA:EPA ratio and measured severity of the illness. The results of this study are not conclusive due to its design (no control group), nevertheless it adds to previous findings and indicates the need for further randomised, controlled trails of omega-3 with ADHD children.
Click here to read the study
A randomised, controlled trail provides strong evidence of the efficacy of omega-3 for children with ADHD
A randomised, double-blind (i.e. both researchers and participants were unaware of who was receiving the active supplement), placebo-controlled trial was conducted, investigating the effects of 6 weeks of supplementation with 1.5 g/d of omega-3 fatty acids, as compared to an inactive placebo supplement, in 13 children (aged 5-17) with autistic disorders accompanied by severe tantrums, aggression, or self-injurious behaviour. A significant effect of the active supplement was observed on hyperactivity and repetitive behaviour; although small the study provides robust preliminary evidence of the efficacy of omega-3 supplements for ADHD.
Click here to read the study abstract.
Omega-3 fatty acids may have therapeutic benefits in childhood depression
Depressive disorders are more common in children than commonly believed. Following successful research in adults this study recruited 28 patients, aged 6-12, and randomised them to receive either an omega-3 fatty acid supplement or a placebo. Ratings on the Childhood Depression Rating Scale (CDRS), Children's Depression Inventory (CDI), and Clinical Global Impression (CGI) at baseline and at 2, 4, 8, 12 and 16 weeks. A highly significant improvement of symptoms was observed with the omega-3 supplement.
Click here to read the study abstract.
An open label trail of omega-3 fatty acid supplements for ADHD
In this study 9 children with were supplemented with 16.2 g EPA/DHA daily; the dosage was adjusted at 4 weeks based on the observed blood plasma ratio of arachidonic acid (AA) to EPA, the aim was for this ratio to reach a level normally found in the Japanese population. A psychiatrist reported significant improvements in behaviour (inattention, hyperactivity, oppositional/defiant behaviour, and conduct disorder); there was also a significant correlation between the reduction in the AA:EPA ratio and measured severity of the illness. The results of this study are not conclusive due to its design (no control group), nevertheless it adds to previous findings and indicates the need for further randomised, controlled trails of omega-3 with ADHD children.
Click here to read the study
A randomised, controlled trail provides strong evidence of the efficacy of omega-3 for children with ADHD
A randomised, double-blind (i.e. both researchers and participants were unaware of who was receiving the active supplement), placebo-controlled trial was conducted, investigating the effects of 6 weeks of supplementation with 1.5 g/d of omega-3 fatty acids, as compared to an inactive placebo supplement, in 13 children (aged 5-17) with autistic disorders accompanied by severe tantrums, aggression, or self-injurious behaviour. A significant effect of the active supplement was observed on hyperactivity and repetitive behaviour; although small the study provides robust preliminary evidence of the efficacy of omega-3 supplements for ADHD.
Click here to read the study abstract.
Omega-3 fatty acids may have therapeutic benefits in childhood depression
Depressive disorders are more common in children than commonly believed. Following successful research in adults this study recruited 28 patients, aged 6-12, and randomised them to receive either an omega-3 fatty acid supplement or a placebo. Ratings on the Childhood Depression Rating Scale (CDRS), Children's Depression Inventory (CDI), and Clinical Global Impression (CGI) at baseline and at 2, 4, 8, 12 and 16 weeks. A highly significant improvement of symptoms was observed with the omega-3 supplement.
Click here to read the study abstract.